Optimind Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
For the six months, net loss was USD 0.073407 million compared to USD 0.068953 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.